Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Lenalidomide
Therapeutic Area: Oncology Product Name: Revlimid
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Bristol-Myers Squibb
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 10, 2020
Details:
Natco Pharma has entered into a settlement agreement with Celgene (now part of Bristol-Myers Squibb) for the product Lenalidomide Capsules in Canada.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
